Evidence map›Paper›PMID 37426355›Full record

ArticleiScience2023

Early TRAIL-engagement elicits potent multimodal targeting of melanoma by CD34

Amanda A van Vliet, Ella Peters, Denise Vodegel, Daniëlle Steenmans, Monica Raimo, Susan Gibbs, Tanja D de Gruijl, Adil D Duru, Jan Spanholtz, Anna-Maria Georgoudaki

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Cellular immunotherapy in melanoma: the next frontier in cancer treatment.Journal of experimental & clinical cancer research : CR · 2026
    Review
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Amanda A van VlietGlycostem Therapeutics, Kloosterstraat 9, 5349 AB Oss, the Netherlands.
Ella PetersGlycostem Therapeutics, Kloosterstraat 9, 5349 AB Oss, the Netherlands.
Denise VodegelGlycostem Therapeutics, Kloosterstraat 9, 5349 AB Oss, the Netherlands.
Daniëlle SteenmansGlycostem Therapeutics, Kloosterstraat 9, 5349 AB Oss, the Netherlands.
Monica RaimoGlycostem Therapeutics, Kloosterstraat 9, 5349 AB Oss, the Netherlands.
Susan GibbsDepartment of Molecular Cell Biology and Immunology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, the Netherlands.
Tanja D de GruijlDepartment of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, the Netherlands.
Adil D DuruGlycostem Therapeutics, Kloosterstraat 9, 5349 AB Oss, the Netherlands.
Jan SpanholtzGlycostem Therapeutics, Kloosterstraat 9, 5349 AB Oss, the Netherlands.
Anna-Maria GeorgoudakiGlycostem Therapeutics, Kloosterstraat 9, 5349 AB Oss, the Netherlands.
Amsterdam University Medical Centers · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Umbilical cord blood (UCB) CD34

Indexed as

CancerComponents of the immune systemTherapy

Identifiers

PMID37426355
PMCPMC10329179
OpenAlexW4379930319

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.